<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Anc Sci Life</journal-id><journal-id journal-id-type="iso-abbrev">Anc Sci Life</journal-id><journal-id journal-id-type="publisher-id">ASL</journal-id><journal-title-group><journal-title>Ancient Science of Life</journal-title></journal-title-group><issn pub-type="ppub">0257-7941</issn><issn pub-type="epub">2249-9547</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26283807</article-id><article-id pub-id-type="pmc">4535070</article-id><article-id pub-id-type="publisher-id">ASL-34-216</article-id><article-id pub-id-type="doi">10.4103/0257-7941.160866</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of herbomineral compounds and <italic>pathya</italic> (Ayurvedic dietary regime and physical exercise) in the management of <italic>Yak&#x01e5b;t Roga</italic> (Non-alcoholic fatty liver disease)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Singhal</surname><given-names>Pragya</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Nesari</surname><given-names>Tanuja</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Girja Shankar</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib></contrib-group><aff id="aff1">Department of Kayachikitsa, Ch. Brahm Prakash Ayurved Charak Sansthan, New Delhi, India</aff><aff id="aff2"><label>1</label>Department of Dravyaguna, Ch. Brahm Prakash Ayurved Charak Sansthan, New Delhi, India</aff><aff id="aff3"><label>2</label>Department of Pathology, Ch. Brahm Prakash Ayurved Charak Sansthan, New Delhi, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold>
Dr. Pragya Singhal, 1003, Oasis Emerald Heights, Ramprastha Greens, Sector 7 Vaishali, Ghaziabad, Uttar Pradesh, India. E-mail: <email xlink:href="pragyasinghalagarwal@gmail.com">pragyasinghalagarwal@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2015</year></pub-date><volume>34</volume><issue>4</issue><fpage>216</fpage><lpage>222</lpage><permissions><copyright-statement>Copyright: &#x000a9; 2015 Ancient Science of Life</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Nonalcoholic fatty liver disease (NAFLD) also called as hepatic steatosis is a manifestation of excessive triglyceride accumulation in the liver. NAFLD has been described by histological features ranging from simple fatty liver, nonalcoholic steatohepatitis, progressive fibrosis, and liver failure.</p></sec><sec id="st2"><title>Objective:</title><p>The objective was to evaluate the effect of herbomineral drugs and <italic>pathya</italic> (Ayurvedic dietary regime and physical exercise) in the management of NAFLD.</p></sec><sec id="st3"><title>Materials and Methods:</title><p>It is a randomized, retrospective, open-ended study. A total of 32 patients presenting with raised alanine transaminase (&#x0003e;1.5 times normal levels) combined with sonological evidence of fatty liver in the absence of any other detectable cause of liver disease were included in the study. The recruited patients were randomly divided into two groups - The patients in Group-A (<italic>n</italic> = 21) were given a combination of herbomineral drugs <italic>&#x00100;rogyavardhin&#x0012b; va&#x01e6d;i</italic> and <italic>Triphal&#x00101; Guggulu</italic> along with prescription of <italic>pathya</italic> (Ayurvedic dietary regime and physical exercise); the patients in Group-B (<italic>n</italic> = 11) were advised only <italic>pathya</italic>.</p></sec><sec id="st4"><title>Results:</title><p>Group-A (combined therapy group) showed statistically significant improvement in clinical symptoms, biochemical parameters-liver function test, lipid profile, fasting blood sugar, and body mass index (<italic>P</italic> &#x0003c; 0.001) in comparison to Group-B (<italic>pathya</italic> group).</p></sec><sec id="st5"><title>Conclusion:</title><p>Combination of herbomineral drugs along with <italic>pathya</italic> has shown promising results toward the effective management of this metabolic disorder.</p></sec></abstract><kwd-group><title>KEYWORDS</title><kwd>Cryptogenic cirrhosis</kwd><kwd><italic>Medoroga</italic></kwd><kwd>metabolic disorder</kwd><kwd>obesity</kwd><kwd><italic>Yak&#x01e5b;t Roga</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Over the past couple of decades, it has become increasingly clear that nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are the significant causes of liver disease. The prevalence of fatty liver disease in India is found to be as high as 24%,[<xref rid="ref1" ref-type="bibr">1</xref>] which is similar to that reported in some of the Western countries, where it correlates with the prevalence of obesity.</p><p>Metabolic syndrome includes NAFLD as a risk factor in addition to other causes such as visceral obesity, hypertension, dysglycemia, and dyslipidemia. Starting from a simple steatosis, NAFLD can proceed to steatohepatitis and fibrosis. Cirrhosis and/or hepatic carcinoma can be its terminal complications.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>]</p><p>In Ayurveda, NAFLD may be understood as <italic>Yak&#x01e5b;t Roga</italic> (liver disease) and <italic>Medoroga</italic> (obesity).</p><p>A vast spectrum of diseases comes under <italic>Yak&#x01e5b;t Roga</italic> (liver disease) ranging from simple hepatic steatosis to hepatomegaly to liver cirrhosis. According to the <italic>Yogratn&#x00101;kara</italic>, <italic>vid&#x00101;h&#x0012b;</italic> (spicy food) and <italic>abhi&#x01e63;yand&#x0012b; &#x00101;h&#x00101;ra</italic> (food which blocks the channels) leads to <italic>Rakta-kapha du&#x01e63;&#x01e6d;i</italic> which may lead to <italic>Yak&#x01e5b;todara</italic>.[<xref rid="ref5" ref-type="bibr">5</xref>]</p><p>Obesity is a common metabolic disorder, and possibly is one among the oldest documented diseases. In Ayurveda as early as 1500 BC Caraka Samhit&#x00101; described this condition as <italic>Sthaulya</italic> (obesity) and <italic>Medoroga</italic> (diseased state of fat metabolism).[<xref rid="ref6" ref-type="bibr">6</xref>]</p><p>NAFLD is a metabolic disorder of hepatic origin. Thus, the treatment of NAFLD should be directed toward normalization of liver functions as well as to the reduction of insulin resistance.</p><p>In this study two herbomineral drugs <italic>&#x00100;rogyavardhin&#x0012b; va&#x01e6d;i</italic> (AV) and <italic>Triphal&#x00101; Guggulu</italic> (TG) along with <italic>pathya</italic> (Ayurvedic dietary regime and physical exercise) [<xref ref-type="table" rid="T1">Table 1</xref>] were given to the patients.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Pathya-Apathya chart</p></caption><graphic xlink:href="ASL-34-216-g001"/></table-wrap><p>Several clinical trials have proven the efficacy of AV in liver disorders.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>]</p><p>Ingredients of the other trial drug (TG) are <italic>Triphal&#x00101;</italic>, <italic>Pippal&#x0012b;</italic>, and <italic>Guggulu</italic>, which are widely indicated in <italic>Medoroga</italic> and were presumed to be helpful reducing in insulin resistance.</p><p><italic>Pathya &#x00101;h&#x00101;ra</italic> includes diets such as <italic>yava</italic>, <italic>mudga</italic>, <italic>madh&#x0016b;daka</italic>, etc., and <italic>vih&#x00101;ra</italic> includes <italic>vy&#x00101;y&#x00101;ma as</italic> described in Caraka Samhit&#x00101; in the context of <italic>Sthaulya cikits&#x00101;</italic> were also advised along with herbomineral drugs.[<xref rid="ref6" ref-type="bibr">6</xref>]</p><p>The objective of the study was to examine the combined effect of two herbomineral drugs AV and TG along with <italic>pathya</italic> (Ayurvedic dietary regime and physical exercise) in the treatment of <italic>Yak&#x01e5b;t Roga</italic> vis-&#x000e0;-vis NAFLD.</p><p>This study revealed the effect of herbomineral drugs AV and TG along with <italic>pathya</italic> (Ayurvedic dietary regime and physical exercise) in the management of NAFLD.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Study design</title><p>This retrospective, controlled, open labelled, series clinical study was conducted between 2011 and 2013 on 32 patients.</p></sec><sec id="sec2-2"><title>Selection of cases</title><sec id="sec3-1"><title>Inclusion criteria</title><p>
<list list-type="bullet"><list-item><p>Clinical signs and symptoms suggesting of NAFLD/<italic>Yak&#x01e5b;t Roga</italic>, that is, pain in right upper quadrant/epigastric region of the abdomen, feeling of nausea, and vomiting, loss of appetite, burning sensation in the abdomen</p></list-item><list-item><p>Ultrasonography (USG) abdomen/or other scanning modalities such as contrast-enhanced computed tomography (CECT) abdomen showing fatty infiltration of the liver</p></list-item><list-item><p>Biochemical: Liver function tests showing raised alanine transaminases (ALT) levels approximately more than 1.5 times the normal limits with/without raised lipid profile and fasting blood glucose levels within normal limits.</p></list-item></list>
</p></sec><sec id="sec3-2"><title>Exclusion criteria</title><p>
<list list-type="bullet"><list-item><p>Patients in whom alcohol intake exceeded 20 g/day (history of alcohol intake was taken separately from the patients and close relatives)</p></list-item><list-item><p>Patients with positive markers of other liver diseases such as viral hepatitis, autoimmune hepatitis, Wilson's disease, alpha 1 antitrypsin deficiency, hemochromatosis.</p></list-item></list>
</p></sec></sec><sec id="sec2-3"><title>Trial drugs</title><p>Two classical herbomineral drugs were selected for the present study:</p><p>
<list list-type="bullet"><list-item><p>AV: As per Rasaratna sammuccaya[<xref rid="ref9" ref-type="bibr">9</xref>] (parts of ingredients taken by weight)</p></list-item></list>
</p><p><italic>&#x0015a;uddha P&#x00101;rada</italic> 1 part, <italic>&#x0015a;uddha Gandhaka</italic> 1 part, <italic>Loha Bhasma</italic> 1 part, <italic>Abhraka Bhasma</italic> 1 part, <italic>T&#x00101;mra Bhasma</italic> 1 part, <italic>Har&#x0012b;tak&#x0012b;</italic> 2 part, <italic>Vibh&#x0012b;tak&#x0012b;</italic> 2 part, <italic>&#x00100;malak&#x0012b;</italic> 2 part, <italic>&#x0015a;hilajatu</italic> 3 part, <italic>Guggulu</italic> 4 part, <italic>Era&#x01e47;&#x01e0d;a</italic> 4 part, <italic>Ka&#x01e6d;uk&#x0012b;</italic> 22 part. <italic>Bh&#x00101;van&#x00101;</italic> with Juice extract of <italic>Nimba patra</italic>.</p><p>Dose: Two tablets of 125 mg twice daily after meals for 3 months.</p><p>
<list list-type="bullet"><list-item><p>TG: As per &#x0015a;&#x00101;r&#x01e45;gadhara Sa&#x01e43;hit&#x00101;[<xref rid="ref10" ref-type="bibr">10</xref>] (parts of ingredients taken by weight) <italic>Triphal&#x00101;</italic> (<italic>Har&#x0012b;tak&#x0012b;</italic> 1 part, <italic>Vibh&#x0012b;tak&#x0012b;</italic> 1 part, <italic>&#x00100;malak&#x0012b;</italic> 1 part), <italic>Pippal&#x0012b;</italic> 1 part, <italic>Guggulu</italic> 1 part.</p></list-item></list>
</p><p>Dose: Two tablets of 125 mg twice daily after meals for 3 months.</p></sec><sec id="sec2-4"><title>Grouping of patients</title><p>The selected patients were randomly divided into two groups namely Group A and Group B.</p><sec id="sec3-3"><title>Group-A (combined therapy group)</title><p>A total of 21 patients were included in this group and were administered to herbomineral drugs (AV and TG) along with Ayurvedic dietary regime and physical exercise, that is, <italic>pathya &#x00101;h&#x00101;ra</italic>/<italic>vih&#x00101;ra</italic> which includes <italic>yava</italic>, <italic>madh&#x0016b;daka</italic>, <italic>vy&#x00101;y&#x00101;ma</italic>, etc.</p></sec><sec id="sec3-4"><title>Group-B (pathya Group)</title><p>Totally, 11 patients of NAFLD were included in this group and were subjected to only Ayurvedic dietary regime and physical exercise, that is, <italic>pathya</italic>.</p></sec></sec><sec id="sec2-5"><title>Criteria of assessment</title><p>Clinical signs and symptoms: <italic>Udara&#x0015b;&#x0016b;la</italic> (pain in abdomen), <italic>utkle&#x0015b;a</italic> (feeling of nausea and vomiting), <italic>aruci</italic> (loss of appetite), <italic>h&#x01e5b;tka&#x01e47;&#x01e6d;had&#x00101;ha</italic> (heartburn), etc., were assessed before and after the treatment. Clinical assessment was made by grading as 0, 1, 2, and 3 on the basis of severity.</p><p>Anthropometric measurement: Weight, height ratio (body mass index [BMI]).</p><p>Biochemical: Serum AST, serum ALT levels, serum triglycerides, fasting blood sugar levels</p><p>Radiological: USG abdomen/CECT abdomen.</p></sec><sec id="sec2-6"><title>Follow-ups</title><p>Total duration of the study was 3 months in which regular follow-ups of the enrolled patients were being done every 15 days. All biochemical investigations were done before starting and after every 1 month of treatment and scanning was done at the beginning and at the end of treatment. USG was done before and after 3 months of the treatment.</p></sec><sec id="sec2-7"><title>Statistical analysis</title><p>The data obtained in the clinical study before and after treatment was expressed in terms of mean, standard deviation with &#x0201c;<italic>n</italic>&#x0201d; as the number of observations. As the sample size is small (<italic>n</italic> ~ 30) paired <italic>t</italic>-test was applied to compare basal and final values. Level of significance was taken as <italic>P</italic> &#x0003c; 0.05. (Abbreviations: SD = Standard deviation, SE = Standard error, <italic>P</italic> = Actual probability value, <italic>n</italic> = number of observations).</p></sec></sec><sec id="sec1-3"><title>OBSERVATIONS AND RESULTS</title><p>Out of 32 patients in the study, 12 patients were female and 20 patients were male which showed male predominance in the study. 81% of the patients were in between the age group of 25 and 55 years [<xref ref-type="table" rid="T2">Table 2</xref>]. Average BMI of the patients was 27.08 &#x000b1; 2.20 kg/m<sup>2</sup> ranging from 23.82 to 32.06 kg/m<sup>2</sup>.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Demographic profile</p></caption><graphic xlink:href="ASL-34-216-g002"/></table-wrap><p>In our study, approximately 62% patients belong to the rural area and most of them were vegetarian with significant history of intake of plenty of milk and milk products (68%) and also with a history of excessive intake of spicy foods such as chillies (46%). 56.25% of patients didn&#x02019;t do much of physical exercise and 40% had the habit of <italic>div&#x00101;svapana</italic> (day/afternoon sleeping). 40% of patient were having <italic>kapha</italic> predominant <italic>prak&#x01e5b;ti</italic> and 62.5% were having <italic>kapha-paittika prak&#x01e5b;ti</italic> [<xref ref-type="table" rid="T2">Table 2</xref>].</p><p>About 76% of enrolled patients presented with <italic>udara&#x0015b;&#x0016b;la</italic>, that is, vague abdominal pain in right upper quadrant or in the epigastric region which was not affected by meals.</p><p>About 55% of the total patients had gastrointestinal complaints like <italic>utkle&#x0015b;a</italic> (feeling of nausea) and <italic>chardi</italic> (vomiting) and heaviness in the abdomens which are <italic>kapha</italic> predominant symptoms.</p><p>About 25% of patients presented with <italic>h&#x01e5b;tka&#x01e47;&#x01e6d;had&#x00101;ha</italic> (burning in the epigastric region) which showed the <italic>paittika</italic> nature of the disease.</p><p>In the present study, 21 patients presented with Grade-1 fatty changes, nine patients showed Grade-2 fatty changes, and two patients presented with Grade-3 fatty changes through imaging studies.</p><p>Eighteen patients showed raised triglyceride levels above the normal limits, and 10 patients had shown raised blood sugar levels [<xref ref-type="table" rid="T3">Table 3</xref>].</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Prevalence of individual components of metabolic syndrome</p></caption><graphic xlink:href="ASL-34-216-g003"/></table-wrap><p>Combined therapy group (Group-A) showed significant improvement in their clinical symptoms such as <italic>udara&#x0015b;&#x0016b;la</italic>, <italic>Aruci</italic>, <italic>utkle&#x0015b;a</italic>, <italic>and h&#x01e5b;tka&#x01e47;&#x01e6d;had&#x00101;ha</italic> (<italic>P</italic> &#x0003c; 0.001) after treatment, whereas the <italic>pathya</italic> group (Group-B) did not show significant improvement in clinical symptoms, that is, <italic>aruci</italic>, <italic>utkle&#x0015b;a</italic>, and <italic>h&#x01e5b;tka&#x01e47;&#x01e6d;had&#x00101;ha</italic> (<italic>P</italic> &#x0003e; 0.05) [<xref ref-type="table" rid="T4">Table 4</xref>].</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Effect of treatment on clinical symptoms</p></caption><graphic xlink:href="ASL-34-216-g004"/></table-wrap><p>In the combined therapy group (Group-A) after 3 months of treatment, the mean BMI was reduced from 27.18 &#x000b1; 2.20 to 25.61 &#x000b1; 2.15. The mean ALT levels of the patients before treatment were 67.15 &#x000b1; 0.93 which was reduced to 42.33 &#x000b1; 3.11 after the treatment, which was statistically highly significant. Triglyceride levels reduced from initial value of 195 &#x000b1; 35.64 to 166.92 &#x000b1; 25.49 [<xref ref-type="table" rid="T5">Table 5</xref>].</p><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Effect of treatment on biochemical parameters and BMI</p></caption><graphic xlink:href="ASL-34-216-g005"/></table-wrap><p>In <italic>pathya</italic> group (Group-B) after 3 months of following <italic>pathya</italic>, the mean BMI was reduced from 26.97 &#x000b1; 1.79 to 26.25 &#x000b1; 1.82. The mean ALT levels of the patients before treatment were 65.69 &#x000b1; 0.79 which was reduced to 58.82 &#x000b1; 7.73 after the 3 months. Initial triglycerides levels before treatment were 179.83 &#x000b1; 15.85 which was reduced to 167.0 &#x000b1; 13.32 [<xref ref-type="table" rid="T5">Table 5</xref>]. The above results were statistically significant.</p><p>USG findings of Group-A showed normal scan in 12 patients of Grade-1 fatty changes and three patients had shown persisting mild fatty changes in comparison to their previous scans. One out of five patients with Grade-2 fatty liver showed normal sonography, three patients improved to Grade-1 fatty liver, and one patient had mild fatty infiltration. USG finding of patient with Grade-3 fatty infiltration had shown decreased echogenicity in comparison to her previous scan with Grade-2 changes.</p><p>In Group-B, six patients presented with Grade-1 fatty changes, four patients showed Grade-2 fatty changes and one patient presented with Grade-3 fatty changes. After 3 months of strict dietary restriction in Group-B patients four patients showed Grade-1 fatty changes, two patient with Grade-2 fatty changes and two patients showed mild fatty infiltration whereas no changes were found in the patient with Grade-3 fatty changes.</p><p>Group-A (combined therapy Group) had shown significant improvement in clinical signs and symptoms and biomedical parameters in comparison to Group-B (<italic>pathya</italic> Group).</p></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Our study demonstrates NAFLD to be a disease of middle age group with a mean age at a presentation being 37 years. Out of 32 patients, 20 patients were males. The reason for this male predominance has been described as a higher waist to hip ratio in men as compared to women, an indicator of central obesity and insulin resistance. This predilection of males to this disease has been seen not only in other studies from India,[<xref rid="ref1" ref-type="bibr">1</xref>] but also in the United States.[<xref rid="ref11" ref-type="bibr">11</xref>]</p><p>Available data show that majority of Indian patients with NAFLD had overweight or obesity as per Asia-Pacific criteria[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref12" ref-type="bibr">12</xref>] (Patients with BMI of more than 23 were seen to be overweight and those with a BMI &#x0003e; 25 were labelled as obese by Asian standards, even though they do not have the kind of morbid obesity as seen in patients from the West). The mean BMI of the patients in our study was 27.08 &#x000b1; 2.20 kg/m<sup>2</sup> which was similar to data available in other studies from India,[<xref rid="ref1" ref-type="bibr">1</xref>] but significantly lower than what has been described in the Western populations, where the mean BMI has always been reported to be above 30.[<xref rid="ref13" ref-type="bibr">13</xref>] Indian patients despite having a lower BMI have similar fat percentage as the Western population.</p><p>About 68% of the total patients were having a history of intake of <italic>abhi&#x01e63;yand&#x0012b; bhojana</italic> (food which blocks the channels such as milk products) and 46% of patients had the history of intake of spicy food. These type of food habit lead to <italic>kapha&#x02013;pitta du&#x01e63;&#x01e6d;i</italic> and <italic>rakta du&#x01e63;&#x01e6d;i</italic> which may lead to <italic>Yak&#x01e5b;t Roga</italic>.[<xref rid="ref5" ref-type="bibr">5</xref>]</p><p>Majority of patients of NAFLD had nausea/vomiting and burning in the epigastric region along with pain in the abdomen, which showed <italic>kapha-pitta</italic> predominance of the disease.[<xref rid="ref5" ref-type="bibr">5</xref>]</p><p>In our study, 21 patients had minimal or mild inflammation (Grade-1). Moderate (Grade-2) inflammation was present in nine patients and severe (Grade-3) inflammation was present in only two patients. None of our patients had advanced liver disorder like liver cirrhosis.</p><p>This is in contrast to the reported series from the West where advanced fibrosis or cirrhosis has been demonstrated to be present in up to 50% of NAFLD data.[<xref rid="ref2" ref-type="bibr">2</xref>] Recently, there have been reports linking the development of hepatocellular carcinoma to NASH.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>]</p><p>Out of 32 patients, 18 patients showed raised triglycerides levels and 10 patients showed raised blood sugar levels, which was indicative of metabolic association of the disease [<xref ref-type="table" rid="T3">Table 3</xref>].</p><p>Our study shows that factors associated with severity of disease, that is, age &#x0003e;35 years, BMI &#x0003e;25 kg/m<sup>2</sup>, cholesterol levels &#x0003e;200 mg%, triglyceride levels &#x0003e;150 mg% were associated in patients with advanced grade of inflammation (Grade-2 fatty liver Grade-3 fatty liver) [<xref ref-type="table" rid="T6">Table 6</xref>].</p><table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Factors associated with advanced grade of inflammation</p></caption><graphic xlink:href="ASL-34-216-g006"/></table-wrap><sec id="sec2-8"><title>Effect of the treatment</title><p>Patients in the combined therapy Group (Group-A) showed significant improvement in their clinical symptoms, biochemical parameters (ALT, triglycerides, fasting blood sugar levels), as well as in BMI after the completion of therapy in comparison to <italic>pathya</italic> group (Group-B). This proves the superiority of combined therapy over <italic>pathya</italic> therapy (Ayurvedic dietary regime and physical exercise) in treating this metabolic disorder [Tables <xref ref-type="table" rid="T4">4</xref> and <xref ref-type="table" rid="T5">5</xref>].</p><p>Group-A showed significant improvement in clinical symptoms viz., pain in abdomen, nausea-vomiting, loss of appetite, and burning sensation in the epigastric region.</p><p>The effect of the treatment in biochemical parameters of combined therapy group (Group-A) was encouraging. Patients of Group-A had their ALT levels move toward normalization and there was also a significant mean decrease in their triglyceride levels after the treatment.</p><p>Mean BMI of the patients of Group-A decreased from 27.18 &#x000b1; 2.20 to 25.61 &#x000b1; 2.15 kg/m<sup>2</sup>, which was highly significant (<italic>P</italic> &#x0003c; 0.001).</p><p>The overall result of the treatment of Group-A implied that combination of herbomineral drugs along with <italic>pathya/apathya</italic> were not only helpful in improving liver functions, but were also supportive in reducing the BMI and triglyceride levels and hence reduced the insulin resistance.</p><p>Patients in Group-B showed improvement in their ALT levels and mean BMI, but did not show marked improvement as compared to Group-A [<xref ref-type="table" rid="T5">Table 5</xref>]. This suggests the significance of dietary restrictions and physical exercises in the management of NAFLD, but not to the extent of treatment with Ayurvedic drugs.</p></sec><sec id="sec2-9"><title>Probable mode of action of Trial drugs: (<italic><italic>&#x00100;rogyavardhin&#x0012b; va&#x01e6d;i</italic> and Triphal&#x00101; Guggulu</italic>)</title><p><italic>&#x00100;rogyavardhin&#x0012b; va&#x01e6d;i</italic> contains <italic>Ka&#x01e6d;uk&#x00101;</italic> (<italic>Picrorhiza kurroa</italic>) as the major ingredient (50%). <italic>Ka&#x01e6d;uk&#x00101;</italic> is <italic>titka rasa pradh&#x00101;na</italic>, thus helpful in <italic>&#x00101;ma-pachana</italic>. Other ingredients of AV are <italic>Loha Bhasma</italic>, <italic>T&#x00101;mra</italic>, <italic>&#x0015a;ilajatu</italic> (Asphaltum), <italic>Guggulu</italic> (<italic>Commiphora mukul</italic>) which are having <italic>lekhan&#x0012b;ya karma</italic> (action)[<xref rid="ref9" ref-type="bibr">9</xref>] <italic>Triphal&#x00101; (Har&#x0012b;tak&#x0012b;</italic> &#x02013; <italic>Terminalia chebula</italic>; <italic>Vibh&#x0012b;tak&#x0012b;</italic> &#x02013; <italic>Terminalia bellerica; &#x00100;malak&#x0012b;</italic> &#x02013; <italic>Emblica officinalis</italic>) is <italic>d&#x0012b;pan&#x0012b;ya</italic>, <italic>&#x0015b;le&#x01e63;ma-pittaghn&#x0012b;</italic>, <italic>meha-&#x0015b;othaghn&#x0012b;</italic>.[<xref rid="ref14" ref-type="bibr">14</xref>]</p><p><italic>Ka&#x01e6d;uk&#x00101;</italic> is a proven hepatoprotective drug by action as is confirmed by several studies. A study of standardized extracts of <italic>P. kurroa</italic> (<italic>Ka&#x01e6d;uk&#x00101;</italic>), in experimental fatty liver disease in rats showed that <italic>P. kurroa</italic> regressed several features of NAFLD such as lipid content of the liver tissue, morphological regression of fatty infiltration, hypolipidemic activity.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>] Pattanaik <italic>et al.</italic>[<xref rid="ref15" ref-type="bibr">15</xref>] reports lipid peroxidation and free radical scavenging properties of <italic>T&#x00101;mra Bhasma</italic>. Buwa <italic>et al.</italic>[<xref rid="ref16" ref-type="bibr">16</xref>] has confirmed the hepatoprotective action of <italic>Abhraka Bhasma</italic>.</p><p>Thus, <italic>&#x00100;rogyavardhin&#x0012b; va&#x01e6d;i</italic> acts as primarily a hepatoprotective and thereby was helpful in improving liver functions in patients of NAFLD.</p><p><italic>Triphal&#x00101; Guggulu</italic> is a mixture of (i) <italic>Triphal&#x00101;</italic> (<italic>Har&#x0012b;tak&#x0012b;</italic> &#x02013; <italic>Terminalia chebula</italic>; <italic>Vibh&#x0012b;tak&#x0012b;</italic> &#x02013; <italic>Terminalia</italic> bellerica; <italic>&#x00100;malak&#x0012b;</italic> &#x02013; <italic>Emblica officinalis</italic>), (ii) <italic>Pippal&#x0012b;</italic> (<italic>Piper longum</italic>), and (iii) <italic>Guggulu</italic> (<italic>Commiphora mukul</italic>) combined using <italic>bh&#x00101;van&#x00101;</italic> of <italic>Triphal&#x00101;</italic> decoction. <italic>Triphal&#x00101;</italic> has <italic>d&#x0012b;pan&#x0012b;ya</italic> action of improving metabolic fire, <italic>&#x0015b;le&#x01e63;ma-pittaghn&#x0012b;</italic>, <italic>meha-&#x0015b;othaghn&#x0012b;</italic> (improving urinary disorders and swelling), <italic>ras&#x00101;yan&#x0012b;</italic> (improving rejuvenating power).[<xref rid="ref10" ref-type="bibr">10</xref>] <italic>Pippal&#x0012b;</italic> is <italic>medah&#x02013;kaphan&#x00101;&#x0015b;aka</italic> (reducing body fat) and <italic>Guggulu</italic> is <italic>ati-lekhana</italic>, <italic>srota&#x0015b;&#x0015b;odhaka</italic> (Purifier of the channels).[<xref rid="ref14" ref-type="bibr">14</xref>]</p><p>Thus, TG is <italic>lekhan&#x0012b;ya</italic> by action and thereby useful in reducing the triglyceride levels along with body fat in patients of NAFLD.</p></sec><sec id="sec2-10"><title>Role of <italic>pathya</italic>/<italic>Apathya</italic> in nonalcoholic fatty liver disease</title><p><italic>Pathya &#x00101;h&#x00101;ra</italic> such as <italic>madhu</italic>, <italic>yava</italic>, etc., are <italic>r&#x0016b;k&#x01e63;a</italic> in <italic>gu&#x01e47;a</italic> (property), <italic>&#x0015b;le&#x01e63;ma-medohara</italic>, and <italic>lekhan&#x0012b;ya</italic> in <italic>karma</italic> (action).[<xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref>] <italic>Mudga</italic> is <italic>kapha-pitta n&#x00101;&#x0015b;aka. Pathya vih&#x00101;ra</italic> such as <italic>vy&#x00101;y&#x00101;ma</italic> (Physical exercise), which was advised to the patients of NAFLD, has been counted as a type of <italic>langhana</italic> and was, therefore, helpful in reducing body fat.[<xref rid="ref19" ref-type="bibr">19</xref>]</p><p>Thus, the recommended Ayurvedic diet as per the constitution of patient (<italic>pathya &#x00101;h&#x00101;ra</italic>) and exercises (<italic>pathya vih&#x00101;ra</italic>) were helpful in reducing BMI. <italic>Pathya</italic> supported not only in reducing insulin resistance but was also useful in reducing the fat accumulated in the liver thus improving the liver functions. We can thus infer that <italic>pathya &#x00101;h&#x00101;ra</italic>/<italic>vih&#x00101;ra</italic> proved useful as an adjunct therapy for management of NAFLD.</p></sec></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>NAFLD is a metabolic syndrome of hepatic origin mostly occurring in middle-aged males and commonly associated with obesity.</p><p>Substances which possess <italic>lekhan&#x0012b;ya</italic> and <italic>medohara karma</italic> (fat reducing action) would be beneficial in NAFLD patients because they decrease the body fat and thus not only improve lipid profile and BMI but also may be helpful in improving the liver function.</p><p><italic>Pathya</italic> (Ayurvedic dietary regime and physical exercise) alone has not been found sufficient to treat this syndrome. Instead, a combination of herbomineral drugs (AV and TG) and <italic>pathya</italic>/apathya have resulted in significant improvement in liver functions and BMI of NAFLD patients.</p><p>To get more significant results, this study needs to be conducted on larger sample size.</p><sec id="sec2-11"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec id="sec2-12"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SP</given-names></name><name><surname>Nayak</surname><given-names>S</given-names></name><name><surname>Swain</surname><given-names>M</given-names></name><name><surname>Rout</surname><given-names>N</given-names></name><name><surname>Mallik</surname><given-names>RN</given-names></name><name><surname>Agrawal</surname><given-names>O</given-names></name><name><surname>et0</surname><given-names>al</given-names></name></person-group><article-title>Prevalence of nonalcoholic fatty liver disease in coastal Eastern India: A preliminary ultrasonographic survey</article-title><source>Trop Gastroenterol</source><year>2004</year><volume>25</volume><fpage>76</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15471321</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matteoni</surname><given-names>CA</given-names></name><name><surname>Younossi</surname><given-names>ZM</given-names></name><name><surname>Gramlich</surname><given-names>T</given-names></name><name><surname>Boparai</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name><name><surname>McCullough</surname><given-names>AJ</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity</article-title><source>Gastroenterology</source><year>1999</year><volume>116</volume><fpage>1413</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10348825</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>Leone</surname><given-names>N</given-names></name><name><surname>Vanni</surname><given-names>E</given-names></name><name><surname>Marchesini</surname><given-names>G</given-names></name><name><surname>Brunello</surname><given-names>F</given-names></name><name><surname>Carucci</surname><given-names>P</given-names></name><etal/></person-group><article-title>Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma</article-title><source>Gastroenterology</source><year>2002</year><volume>123</volume><fpage>134</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">12105842</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>E</given-names></name><name><surname>Yatsuji</surname><given-names>S</given-names></name><name><surname>Kaneda</surname><given-names>H</given-names></name><name><surname>Taniai</surname><given-names>M</given-names></name><name><surname>Tokushige</surname><given-names>K</given-names></name><etal/></person-group><article-title>Nonalcoholic steatohepatitis: Cirrhosis, hepatocellular carcinoma, and burnt-out NASH</article-title><source>J Gastroenterol</source><year>2004</year><volume>39</volume><fpage>1215</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15622489</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Shastri</surname><given-names>SB</given-names></name></person-group><article-title>Yoga Ratnakar, Commentary by Vaidya Sri Laxmipati Shastri. Udara Rogachikitsa: Ver. 17</article-title><year>2009</year><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhamba Prakashan</publisher-name><fpage>104</fpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="book"><article-title>Agnivesh, Charak Samhita, Hindi commentary by Kashinath Pandey and Gorakh Nath Chaturvedi, Sutra Sthana 21: Ver. 25-28</article-title><year>1998</year><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhamba Bharti Academy</publisher-name><fpage>415</fpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antarkar</surname><given-names>DS</given-names></name><name><surname>Tathed</surname><given-names>PS</given-names></name><name><surname>Vaidya</surname><given-names>AB</given-names></name></person-group><article-title>A pilot phase II trial with arogya-wardhani and Punarnavadi-Kwath in viral hepatitis</article-title><source>Panminerva Med</source><year>1978</year><volume>20</volume><fpage>157</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">757281</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shetty</surname><given-names>SN</given-names></name><name><surname>Mengi</surname><given-names>S</given-names></name><name><surname>Vaidya</surname><given-names>R</given-names></name><name><surname>Vaidya</surname><given-names>AD</given-names></name></person-group><article-title>A study of standardized extracts of <italic>Picrorhiza kurroa</italic> Royle ex Benth in experimental nonalcoholic fatty liver disease</article-title><source>J Ayurveda Integr Med</source><year>2010</year><volume>1</volume><fpage>203</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">21547049</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Giri</surname><given-names>K</given-names></name></person-group><article-title>Vagabhatta, Rasratnnasammuchaya, Hindi commentary Rasaprabha by Indradev Tripathi. Kustha Rogadhikar. Ver. 87-93</article-title><year>2009</year><publisher-loc>Varanasi</publisher-loc><publisher-name>Published by Chaukhamba Sanskrit Sansthan</publisher-name><fpage>252</fpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="book"><article-title>Sharangdhara's Sharangdhara Samhita with Commentary by Shailza Srivastava. Madhyamakhanda 7. Ver. 82-83</article-title><year>2009</year><publisher-loc>Varanasi</publisher-loc><publisher-name>Published by Chaukhamba Orientalia</publisher-name><fpage>205</fpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruhl</surname><given-names>CE</given-names></name><name><surname>Everhart</surname><given-names>JE</given-names></name></person-group><article-title>Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States</article-title><source>Gastroenterology</source><year>2003</year><volume>124</volume><fpage>71</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12512031</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="book"><collab>World Health Organization</collab><article-title>Western Pacific Region. Asia-Pacific perspective. Redefining Obesity and its treatment</article-title><year>2000</year><publisher-loc>Sydney, Melbourne, Australia: WHO/IASO/IOTF</publisher-loc><publisher-name>Published by Health Communications Australia Pty Limited</publisher-name></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teli</surname><given-names>MR</given-names></name><name><surname>James</surname><given-names>OF</given-names></name><name><surname>Burt</surname><given-names>AD</given-names></name><name><surname>Bennett</surname><given-names>MK</given-names></name><name><surname>Day</surname><given-names>CP</given-names></name></person-group><article-title>The natural history of nonalcoholic fatty liver: A follow-up study</article-title><source>Hepatology</source><year>1995</year><volume>22</volume><fpage>1714</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7489979</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Chunekar</surname><given-names>KC</given-names></name><name><surname>Pandey</surname><given-names>GS</given-names></name></person-group><article-title>Bhavamishra, Bhavaprakasha Nighantu</article-title><year>2006</year><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhamba Surbharti Academy</publisher-name></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pattanaik</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>AV</given-names></name><name><surname>Pandey</surname><given-names>RS</given-names></name><name><surname>Singh</surname><given-names>BS</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Dixit</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Toxicology and free radicals scavenging property of Tamra bhasma</article-title><source>Indian J Clin Biochem</source><year>2003</year><volume>18</volume><fpage>181</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23105410</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buwa</surname><given-names>S</given-names></name><name><surname>Patil</surname><given-names>S</given-names></name><name><surname>Kulkarni</surname><given-names>PH</given-names></name><name><surname>Kanase</surname><given-names>A</given-names></name></person-group><article-title>Hepatoprotective action of abhrak bhasma, an ayurvedic drug in albino rats against hepatitis induced by CCl4</article-title><source>Indian J Exp Biol</source><year>2001</year><volume>39</volume><fpage>1022</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11883510</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="book"><article-title>Sushruta, Sutra Sthana 45:132, Hindi commentary by Dr Ambika Datt Shastri: Sushruta Samhita, Ayurved Tatva Sandipika</article-title><year>1997</year><edition>11th ed</edition><publisher-loc>Varanasi</publisher-loc><publisher-name>Published by Chaukhamba Sanskrit Sansthan</publisher-name><fpage>180</fpage></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="book"><article-title>Sushruta, Sutra Sthana 46:42, Hindi commentary by Shastri AM. Sushruta Samhita, Ayurved Tatva Sandipika</article-title><year>1997</year><edition>11th ed</edition><publisher-loc>Varanasi</publisher-loc><publisher-name>Published by Chaukhamba Sanskrit Sansthan</publisher-name><fpage>190</fpage></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="book"><article-title>Agnivesha, Charaka Samhita, Hindi commentary by Pandey K, Chaturvedi GN. Sutra Sthana 22: Ver. 18</article-title><year>1998</year><publisher-loc>Varanasi</publisher-loc><publisher-name>Chaukhamba Bharti Academy</publisher-name><fpage>427</fpage></element-citation></ref></ref-list></back></article>